Elisa and Vecima Supercharge Cable Network with DAA to Deliver Gigabit Access to Subscribers in Finland
10.5.2022 16:15:00 EEST | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) announced today that leading Finnish telecommunications operator Elisa has deployed Vecima’s EntraTM Remote MACPHY solution to evolve its network with a next-generation Distributed Access Architecture (DAA). The solution enables Elisa to deploy gigabit broadband and new service experiences to residential subscribers – detached homes and multi-dwelling units – and businesses. In addition, moving to DAA delivers sustainability through digitalization, enabling substantial energy savings.
In Finland’s highly competitive broadband market, Elisa brings highly innovative solutions to its subscribers. Vecima’s Entra DAA solution boasts flexible access node configurations, a cloud-based access controller, multiple video delivery options, and highly scalable capacity. As Elisa looks to maintain its market-leading position, Entra is well matched to forward-looking, strategic architectural plans.
“We are committed to offering our customers the best possible internet experience,” said Antti Salonen, Head of Technology for Fixed Networks at Elisa. “By deploying the Entra solution, we can move our cable access network to the next generation with higher capacity, new service offerings and automated network operations. Vecima’s unique DAA solution provides a flexible and efficient way to leverage our existing IP network to expand to new areas without the increased costs of additional headend equipment.”
To take advantage of untapped, latent capacity in Hybrid Fiber Coax (HFC) networks, the cable access network must be rearchitected and simplified to eliminate analog/RF transmission, replace, or digitize legacy video, and optimize operational costs. Once deployed, a Distribution Access Architecture increases network capacity and performance, lowers total cost of ownership, and reduces power consumption.
The Vecima SC-1D Entra Access Node offers a Remote MACPHY Device in a compact, European form factor. Elisa will deploy the SC-1D managed by the Vecima Entra Access Controller (EAC), which provides centralized control and leverages software-defined networking principles to pave the way for a platform capable of delivering faster connections to end users.
‟As cable operators contend with changes in the competitive landscape, and ever-growing demands for greater capacity and performance, we see growing momentum in the move to DAA,” said Ryan Nicometo, Senior Vice President and General Manager of Vecima’s Video & Broadband Solutions business. “Elisa is building one of the most innovative DAA deployments in the world, and we’re proud to help enable their strategic vision.”
Further information about Vecima’s Entra solution is available at vecima.com/solutions/distributed-access.
About Elisa
Elisa’s mission is a sustainable future through digitalisation. We are a pioneer in telecommunications and digital services, and in 5G. We provide sustainable solutions for over 2.8 million consumer, corporate and public administration customers in our core markets of Finland and Estonia, as well as in over 100 countries internationally. In Finland, Elisa is a market leader in telecommunications, and our international cooperation partners include Vodafone and Tele2. Elisa is listed on the Nasdaq Helsinki. In 2021, our revenue was EUR 2 billion and we employed 5,300 people in more than 20 countries. Elisa is a carbon-neutral company. Learn more at elisa.com
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive.
Learn more at vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509006218/en/
Contact information
Investor Relations
250-881-1982
invest@vecima.com
Media Relations
bernadette.dunn@vecima.com
david.slovensky@vecima.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202613.6.2026 00:31:00 EEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 19:36:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
